vimarsana.com

Page 10 - மைய மருந்து தரநிலை கட்டுப்பாடு ஆர்கநைஸேஶந் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Coronavirus pandemic live updates: Sanitation staff, pharmacists may be on 1st vaccination list : No approval for Covaxin yet, expert panel seeks more data from Bharat Biotech

COVAXIN Bharat Biotech covid vaccine recommended restricted emergency use expert panel DCGI final approval

URL copied Expert panel recommends granting restricted emergency use approval for COVAXIN. A day after a government panel recommended to grant emergency use approval for the Oxford-AstraZeneca s Covishield vaccine for coronavirus, an expert panel on Saturday recommended granting permission for restricted emergency use authorisation for Bharat Biotech s indigenously developed COVID-19 vaccine — Covaxin, ANI reported quoting government sources. The Subject Expert Committee of Central Drug Standard Control Organization on Saturday recommended Bharat Biotech s Covaxin for emergency use in India. The final decision on its approval will, however, be taken by the Drug Controller General of India (DCGI). The committee of experts assessing Coronavirus vaccines had called Hyderabad-based Bharat Biotech for a meeting in the afternoon today, a day after the firm was asked to present more data to get a nod, a top source said on Saturday.

Welcome To IANS Live - LatestNews - Oxford-AstraZeneca Covishield vaccine likely to get nod in India

Photo Credit: IANS IANSLive New Delhi, Jan 1 (IANS) The 10-member Subject Expert Committee of India s Central Drug Standard Control Organisation is likely on Friday to approve emergency use authorisation of the Oxford-AstraZeneca vaccine, top sources told IANS. To get full access of the story, click here to subscribe to IANS News Service © 2021 IANS India Private Limited. All Rights Reserved. The reproduction of the story/photograph in any form will be liable for legal action. For news, views and gossips, follow IANS at Twitter. Update: 01-January-2021

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.